X4 Pharmaceuticals (XFOR) Tops Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts XFOR Hot Sheet
Join SI Premium – FREE
X4 Pharmaceuticals (NASDAQ: XFOR) reported Q2 EPS of ($0.13), $0.06 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $8.81 million versus the consensus estimate of $2.28 million.
For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hillman Solutions (HLMN) Tops Q3 EPS by 1c; Offers Guidance
- Hinge Health, Inc. (HNGE) Tops Q3 EPS by 6c, raises Guidance
- HealthStream (HSTM) Tops Q3 EPS by 2c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
